A Case of Perioral Dermatitis Successfully Treated with Abrocitinib

Perioral dermatitis (POD) is a chronic inflammatory skin disease that primarily affects females between the ages of 16 and 45. Conventional therapies face the challenge of limited efficacy and a high recurrence rate. In this report, we present the case of a 26-year-old male patient with POD who was...

Descripción completa

Detalles Bibliográficos
Autores principales: Teng, Yan, Ren, Mingyang, Ding, Yang, Yang, Xianhong, Fan, Yibin, Tao, Xiaohua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2023
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10612496/
https://www.ncbi.nlm.nih.gov/pubmed/37901150
http://dx.doi.org/10.2147/CCID.S433561
_version_ 1785128713701031936
author Teng, Yan
Ren, Mingyang
Ding, Yang
Yang, Xianhong
Fan, Yibin
Tao, Xiaohua
author_facet Teng, Yan
Ren, Mingyang
Ding, Yang
Yang, Xianhong
Fan, Yibin
Tao, Xiaohua
author_sort Teng, Yan
collection PubMed
description Perioral dermatitis (POD) is a chronic inflammatory skin disease that primarily affects females between the ages of 16 and 45. Conventional therapies face the challenge of limited efficacy and a high recurrence rate. In this report, we present the case of a 26-year-old male patient with POD who was successfully treated using the Janus kinase (JAK) inhibitor, abrocitinib. This treatment exhibited both good efficacy and safety. Abrocitinib, as a JAK inhibitor, holds promise as a potential therapy for cases of POD that might be resistant to conventional therapies.
format Online
Article
Text
id pubmed-10612496
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-106124962023-10-29 A Case of Perioral Dermatitis Successfully Treated with Abrocitinib Teng, Yan Ren, Mingyang Ding, Yang Yang, Xianhong Fan, Yibin Tao, Xiaohua Clin Cosmet Investig Dermatol Case Report Perioral dermatitis (POD) is a chronic inflammatory skin disease that primarily affects females between the ages of 16 and 45. Conventional therapies face the challenge of limited efficacy and a high recurrence rate. In this report, we present the case of a 26-year-old male patient with POD who was successfully treated using the Janus kinase (JAK) inhibitor, abrocitinib. This treatment exhibited both good efficacy and safety. Abrocitinib, as a JAK inhibitor, holds promise as a potential therapy for cases of POD that might be resistant to conventional therapies. Dove 2023-10-24 /pmc/articles/PMC10612496/ /pubmed/37901150 http://dx.doi.org/10.2147/CCID.S433561 Text en © 2023 Teng et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Case Report
Teng, Yan
Ren, Mingyang
Ding, Yang
Yang, Xianhong
Fan, Yibin
Tao, Xiaohua
A Case of Perioral Dermatitis Successfully Treated with Abrocitinib
title A Case of Perioral Dermatitis Successfully Treated with Abrocitinib
title_full A Case of Perioral Dermatitis Successfully Treated with Abrocitinib
title_fullStr A Case of Perioral Dermatitis Successfully Treated with Abrocitinib
title_full_unstemmed A Case of Perioral Dermatitis Successfully Treated with Abrocitinib
title_short A Case of Perioral Dermatitis Successfully Treated with Abrocitinib
title_sort case of perioral dermatitis successfully treated with abrocitinib
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10612496/
https://www.ncbi.nlm.nih.gov/pubmed/37901150
http://dx.doi.org/10.2147/CCID.S433561
work_keys_str_mv AT tengyan acaseofperioraldermatitissuccessfullytreatedwithabrocitinib
AT renmingyang acaseofperioraldermatitissuccessfullytreatedwithabrocitinib
AT dingyang acaseofperioraldermatitissuccessfullytreatedwithabrocitinib
AT yangxianhong acaseofperioraldermatitissuccessfullytreatedwithabrocitinib
AT fanyibin acaseofperioraldermatitissuccessfullytreatedwithabrocitinib
AT taoxiaohua acaseofperioraldermatitissuccessfullytreatedwithabrocitinib
AT tengyan caseofperioraldermatitissuccessfullytreatedwithabrocitinib
AT renmingyang caseofperioraldermatitissuccessfullytreatedwithabrocitinib
AT dingyang caseofperioraldermatitissuccessfullytreatedwithabrocitinib
AT yangxianhong caseofperioraldermatitissuccessfullytreatedwithabrocitinib
AT fanyibin caseofperioraldermatitissuccessfullytreatedwithabrocitinib
AT taoxiaohua caseofperioraldermatitissuccessfullytreatedwithabrocitinib

Ejemplares similares